ClinicalTrials.gg
RecruitingNCT07123857Updated Aug 14, 2025

Impact of Point-of-care Lactate Testing as Triage Supplement on Patient Management Using Manchester Triage System

An interventional study of re-triage in Triage, Emergency Department Triage and Emergency Department Overcrowding, sponsored by University Medical Centre Maribor. Recruiting at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by University Medical Centre Maribor · Not applicable, Interventional, and Screening

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Although the Manchester Triage System (MTS) is widely used and validated internationally, it has some limitations. Its accuracy is moderate, especially for children and the elderly. Rising patient numbers and overcrowded emergency departments increase wait times, sometimes beyond safe limits. In Slovenia, MTS has been in use for 14 years without major updates, despite a significant rise in emergency visits. The yellow triage category (60-minute wait time) includes a very diverse group of patients, some of whom might require faster care. Older patients, in particular, often show atypical symptoms and may be under-triaged. Including rapid bedside lab tests, like blood lactate levels, could improve risk assessment and triage accuracy. Elevated lactate is linked with higher mortality and can help identify critically ill patients more effectively. The proposed study is a prospective, randomized trial involving two groups of patients in the yellow triage category, all of whom will have their capillary blood lactate levels measured. Patients with normal lactate levels will be excluded. Only patients with elevated lactate will be compared. The test group will be re-triaged to the orange category and treated more urgently. The control group, despite also having high lactate levels, will remain in the yellow category, and their elevated lactate values will not be shared with the treating physician. Randomization will be based on the patient's birth date (even days = test group, odd days = control group). Only the nurse will know the result, maintaining physician blinding to avoid the Hawthorne effect-changes in behavior due to awareness of being studied. Standard lab tests will be performed later during treatment as deemed necessary by the attending doctor.

02

Conditions studied

  • Triage
  • Emergency Department Triage
  • Emergency Department Overcrowding
  • Emergency Medicine
03

In context

Lead sponsor

University Medical Centre Maribor is the lead sponsor of 36 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed consent, yellow MTS triage category

Exclusion criteria

Exclusion Criteria:

  • pregnant women, trauma patients, epileptic seizures, adrenergic therapy in prehospital unit
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Control group - No-retriage
  • Experimental
    Test group - Retriage to orange MTS group

    Diagnostic Test: re-triage

Interventions

  • Diagnostic testre-triage

    Patients in the test group will be re-triaged into the orange MTS category.

06

What researchers measure

Primary outcomes

  1. Vasoactive drug use

    Time frame: 30-day

Secondary outcomes

  1. In-hospital mortality

    Time frame: 30-day

  2. ICU admission

    Time frame: 30-day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. The decision not to share IPD is based on privacy concerns, data protection regulations, and institutional policy.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123857
Lead sponsor
University Medical Centre Maribor
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jul 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 14, 2025

Study contacts

Jerica Zaloznik Djordjevic, MD
Contact
jerica.zalo@gmail.com
00386 31 696 858

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion